Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.90 |
| ▸ | HPGD | P15428 | 7/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | CA12 | O43570 | 1/20 | 0.90 |
| ▸ | CA1 | P00915 | 1/20 | 0.90 |
| ▸ | CA2 | P00918 | 1/20 | 0.90 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.90 |
| ▸ | CA4 | P22748 | 1/20 | 0.90 |
| ▸ | CA6 | P23280 | 1/20 | 0.90 |
| ▸ | CA7 | P43166 | 1/20 | 0.90 |
| ▸ | CA9 | Q16790 | 1/20 | 0.90 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.90 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.90 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL28047653 | 1.00 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28120273 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8599857 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28650089 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9982 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9691144 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8596622 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1079228 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29440406 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1262212 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240141142-A1 | POLY(VINYL BUTYRAL) COMPOSITIONS FOR USE WITH SOLAR ADDITIVES | SOLUTIA INC. (US) | 2024-05-02 | — | — | US | claimed |
| EP-4301596-A1 | POLY (VINYL BUTYRAL) COMPOSITIONS FOR USE WITH SOLAR ADDITIVES | Solutia Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| CN-116917121-A | Poly (vinyl butyral) composition for use with solar energy additives | 首诺公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2022187082-A1 | POLY (VINYL BUTYRAL) COMPOSITIONS FOR USE WITH SOLAR ADDITIVES | SOLUTIA INC. (US) | 2022-09-09 | — | — | WO | claimed |
| US-11254779-B1 | Reworkable ionomers | HRL LABORATORIES, LLC (US) | 2022-02-22 | — | — | US | claimed |
| US-20200276213-A1 | HEALTH CARE | ROZMANITH ANTHONY I (US) | 2020-09-03 | — | — | US | claimed |
| US-20180008618-A1 | HEALTH CARE | ROZMANITH ANTHONY I (US) | 2018-01-11 | — | — | US | claimed |
| US-20130004542-A1 | COMPOSITION | INNOVATA LIMITED (GB) | 2013-01-03 | — | — | US | claimed |
| EP-2490670-A2 | COMPOSITION FOR INHALATION | Innovata Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| US-20120132204-A1 | UNIT DOSE DRY POWDER INHALER | INNOVATA BIOMED LIMITED (GB) | 2012-05-31 | — | — | US | claimed |
| EP-1325285-A1 | METHOD OF INKJET PRINTING USING INK HAVING HIGH WETTING AGENT LEVELS | Lexmark International, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-6565871-B2 | For administration of a bioactive material to subcutaneous and intradermal tissue | ELAN DRUG DELIVERY LTD. (GB) | 2003-05-20 | — | — | US | claimed |
| US-6398357-B1 | METHOD TRANSFERS THE IMAGE FROM THE INTERMEDIATE TRANSFER SURFACE TO A FINAL MEDIUM WHILE THE INK IS PARTIALLY WET. | LEXMARK INTERNATIONAL, INC | 2002-06-04 | — | — | US | claimed |
| WO-2002030673-A2 | INTERMEDIATE TRANSFER MEDIUM COATING SOLUTION AND METHOD OF INK JET PRINTING USING COATING SOLUTION | LEXMARK INTERNATIONAL, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2002031443-A1 | METHOD OF INKJET PRINTING USING INK HAVING HIGH WETTING AGENT LEVELS | LEXMARK INTERNATIONAL, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-6357870-B1 | Intermediate transfer medium coating solution and method of ink jet printing using coating solution | LEXMARK INTERNATIONAL, INC. | 2002-03-19 | — | — | US | claimed |
| US-20020012687-A1 | Solid dose delivery vehicle and methods of making same | QDOSE LIMITED (GB) | 2002-01-31 | — | — | US | claimed |
| EP-0415567-A2 | Composition and method for stabilising organic compounds | QUADRANT BIORESOURCES LIMITED (GB) | 1991-03-06 | — | — | EP | claimed |
| EP-0353281-A1 | METHOD OF DRYING MACROMOLECULES | QUADRANT BIORESOURCES LIMITED (GB) | 1990-02-07 | — | — | EP | claimed |
| WO-1989006976-A1 | METHOD OF DRYING MACROMOLECULES | QUADRANT BIORESOURCES LIMITED (GB) | 1989-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004542-A1 | COMPOSITION | MATR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL5 | ALDH1A1 4362/4885KDM4E 2933/4885HPGD 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.